Kyle Doherty

Erdafitinib plus cetrelimab displayed strong responses for patients with metastatic or locally advanced urothelial carcinoma.

Patients with non-small cell lung cancer with brain metastases experienced a favorable safety profile along with efficacy results when treated with atezolizumab plus chemotherapy.

CAR066, showed a favorable safety profile and promising efficacy in the treatment of adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed prior CD19 CAR T-cell therapy.

The addition of neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathological complete response rates and showed a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

For patients with NRG1 fusion–positive cancers, zenocutuzumab represents a promising novel targeted therapeutic option.

Patients with advanced synovial sarcoma who received treatment with catequentinib experienced improved disease control and progression-free survival compared with dacarbazine.

The clinical benefit rate of the neratinib plus fulvestrant combination treatment did not meet the predefined efficacy threshold, but was active in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer.